Vitiligo

New England Journal of Medicine

Volumn 360, Issue 2, 2009, Pages 160-169

  Taïeb, Alain ^a,c   Picardo, Mauro ^b  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

^b SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

^c HÔPITAL SAINT ANDRÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CRYOPYRIN; IMIDAZOLE; SUNSCREEN; COLORING AGENT;

ADULT; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; DEPIGMENTATION; DIAGNOSTIC APPROACH ROUTE; DIFFERENTIAL DIAGNOSIS; FEMALE; GENETIC CODE; HUMAN; MELANOCYTE; MOSAICISM; MYCOSIS; NEUROLOGIC DISEASE; OXIDATIVE STRESS; PATHOGENESIS; PHOTOTHERAPY; PRIORITY JOURNAL; PUVA; QUALITY OF LIFE; REVIEW; RISK FACTOR; SKIN MANIFESTATION; TREATMENT FAILURE; ULTRAVIOLET RADIATION; VITILIGO; MALE; PRACTICE GUIDELINE;

ADRENAL CORTEX HORMONES; ADULT; COLORING AGENTS; FEMALE; HUMANS; MALE; PRACTICE GUIDELINES AS TOPIC; ULTRAVIOLET THERAPY; VITILIGO;

EID: 58149383594     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcp0804388     Document Type: Article

References (48)

1. Howitz J, Brodthagen H, Schwartz M, Thomsen K. Prevalence of vitiligo: epidemiological survey on the Isle of Bornholm, Denmark. Arch Dermatol 1977;113:47-52.
2. Boisseau-Garsaud AM, Garsaud P, Calès-Quist D, Hélénon R, Quénéhervé C, Claire RC. Epidemiology of vitiligo in the French West Indies (Isle of Martinique). Int J Dermatol 2000;39:18-20.
3. Hann SK, Lee HJ. Segmental vitiligo: clinical findings in 208 patients. J Am Acad Dermatol 1996;35:671-4.
4. Taïeb A, Picardo M. The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force. Pigment Cell Res 2007;20:27-35.
5. Gauthier Y, Cario André M, Taïeb A. A critical appraisal of vitiligo etiologic theories: is melanocyte loss a melanocytorrhagy? Pigment Cell Res 2003;16:322-32.
6. Dell'anna ML, Picardo M. A review and a new hypothesis for non-immunological pathogenetic mechanisms in vitiligo. Pigment Cell Res 2006;19:406-11.
7. Attili VR, Attili SK. Lichenoid inflammation in vitiligo - a clinical and histopathologic review of 210 cases. Int J Dermatol 2008;47:663-9.
8. Jin Y, Mailloux CM, Gowan K, et al. NALP1 in vitiligo-associated multiple autoimmune disease. N Engl J Med 2007;356:1216-25.
9. Barona MI, Arrunátegui A, Falabella R, Alzate A. An epidemiologic case-control study in a population with vitiligo. J Am Acad Dermatol 1995;33:621-5.
10. Boissy RE, Manga P. On the etiology of contact/occupational vitiligo. Pigment Cell Res 2004;17:208-14.
11. Lee HS, Chun YS, Hann SK. Nevus depigmentosus: clinical features and histopathologic characteristics in 67 patients. J Am Acad Dermatol 1999;40:21-6.
12. Mason CP, Gawkrodger DJ. Vitiligo presentation in adults. Clin Exp Dermatol 2005;30:344-5.
13. Gauthier Y. The importance of Koebner's phenomenon in the induction of vitiligo vulgaris lesions. Eur J Dermatol 1995;5:704-8.
14. Kakourou T, Kanaka-Gantenbein C, Papadopoulou A, Kaloumenou E, Chrousos GP. Increased prevalence of chronic autoimmune (Hashimoto's) thyroiditis in children and adolescents with vitiligo. J Am Acad Dermatol 2005;53:220-3.
15. Alkhateeb A, Fain PR, Thody A, Bennett DC, Spritz RA. Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. Pigment Cell Res 2003;16:208-14.
16. Liu JB, Li M, Yang S, et al. Clinical profiles of vitiligo in China: an analysis of 3742 patients. Clin Exp Dermatol 2005;30:327-31.
17. Betterle C, Caretto A, De Zio A, et al. Incidence and significance of organ-specific autoimmune disorders (clinical, latent or only autoantibodies) in patients with vitiligo. Dermatologica 1985;171:419-23.
18. Njoo MD, Spuls PI, Bos JD, Westerhof W, Bossuyt PM. Nonsurgical repigmentation therapies in vitiligo: meta-analysis of the literature. Arch Dermatol 1998;134:1532-40.
19. Whitton ME, Ashcroft DM, Barrett CW, Gonzalez U. Interventions for vitiligo. Cochrane Database Syst Rev 2006;1:CD003263.
20. Hamzavi I, Jain H, McLean D, Shapiro J, Zeng H, Lui H. Parametric modeling of narrowband UV-B phototherapy for vitiligo using a novel quantitative tool: the Vitiligo Area Scoring Index. Arch Dermatol 2004;140:677-83.
21. Westerhof W, Nieuweboer-Krobotova L. Treatment of vitiligo with UV-B radiation vs topical psoralen plus UV-A. Arch Dermatol 1997;133:1525-8.
22. Njoo MD, Bos JD, Westerhof W. Treatment of generalized vitiligo in children with narrow-band (TL-01) UVB radiation therapy. J Am Acad Dermatol 2000;42:245-53.
23. Yones SS, Palmer RA, Garibaldinos TM, Hawk JL. Randomized double-blind trial of treatment of vitiligo: efficacy of psoralen-UV-A therapy vs narrowband-UV-B therapy. Arch Dermatol 2007;143:578-84. [Erratum, Arch Dermatol 2007;143:906.]
24. Anbar TS, Westerhof W, Abdel-Rahman AT, El-Khayyat MA. Evaluation of the effects of NB-UVB in both segmental and non-segmental vitiligo affecting different body sites. Photodermatol Photoimmunol Photomed 2006;22:157-63.
25. Passeron T, Ostovari N, Zakaria W, et al. Topical tacrolimus and the 308-nm excimer laser: a synergistic combination for the treatment of vitiligo. Arch Dermatol 2004;140:1065-9.
26. Casacci M, Thomas P, Pacifico A, Bonnevalle A, Paro Vidolin A, Leone G. Comparison between 308-nm monochromatic excimer light and narrowband UVB phototherapy (311-313 nm) in the treatment of vitiligo - a multicentre controlled study. J Eur Acad Dermatol Venereol 2007;21:956-63.
27. Hofer A, Hassan AS, Legat FJ, Kerl H, Wolf P. Optimal weekly frequency of 308-nm excimer laser treatment in vitiligo patients. Br J Dermatol 2005;152:981-5.
28. Yu HS, Wu CS, Yu CL, Kao YH, Chiou MH. Helium-neon laser irradiation stimulates migration and proliferation in melanocytes and induces repigmentation in segmental-type vitiligo. J Invest Dermatol 2003;120:56-64.
29. Parsad D, Pandhi R, Dogra S, Kumar B. Clinical study of repigmentation patterns with different treatment modalities and their correlation with speed and stability of repigmentation in 352 vitiliginous patches. J Am Acad Dermatol 2004;50:63-7.
30. Forschner T, Buchholtz S, Stockfleth E. Current state of vitiligo therapy - evidence-based analysis of the literature. J Dtsch Dermatol Ges 2007;5:467-75.
31. Lan CC, Chen GS, Chiou MH, Wu CS, Chang CH, Yu HS. FK506 promotes melanocyte and melanoblast growth and creates a favourable milieu for cell migration via keratinocytes: possible mechanisms of how tacrolimus ointment induces repigmentation in patients with vitiligo. Br J Dermatol 2005;153:498-505.
32. Hartmann A, Bröcker EB, Hamm H. Occlusive treatment enhances efficacy of tacrolimus 0.1% ointment in adult patients with vitiligo: results of a placebo-controlled 12-month prospective study. Acta Derm Venereol 2008;88:474-9.
33. Mehrabi D, Pandya AG. A randomized, placebo-controlled, double-blind trial comparing narrowband UV-B plus 0.1% tacrolimus ointment with narrowband UV-B plus placebo in the treatment of generalized vitiligo. Arch Dermatol 2006;142:927-9.
34. Lan C, Wu C, Chen G, Yu H. Heliumneon laser and topical tacrolimus combination therapy: novel treatment option for vitiligo without additional photocarcinogenic risks. J Eur Acad Dermatol Venereol 2008 June 23 (Epub ahead of print).
35. Rustin MH. The safety of tacrolimus ointment for the treatment of atopic dermatitis: a review. Br J Dermatol 2007;157:861-73.
36. Falabella R. Treatment of localized vitiligo by autologous minigrafting. Arch Dermatol 1988;124:1649-55.
37. Gauthier Y, Surleve-Bazeille JE. Autologous grafting with noncultured melanocytes: a simplified method for treatment of depigmented lesions. J Am Acad Dermatol 1992;26:191-4.
38. Olsson MJ, Juhlin L. Epidermal sheet grafts for repigmentation of vitiligo and piebaldism, with a review of surgical techniques. Acta Derm Venereol 1997;77:463-6.
39. van Geel N, Ongenae K, De Mil M, Haeghen YV, Vervaet C, Naeyaert JM. Double-blind placebo-controlled study of autologous transplanted epidermal cell suspensions for repigmenting vitiligo. Arch Dermatol 2004;140:1203-8.
40. Rajatanavin N, Suwanachote S, Kulkollakarn S. Dihydroxyacetone: a safe camouflaging option in vitiligo. Int J Dermatol 2008;47:402-6.
41. Ongenae K, Dierckxsens L, Brochez L, van Geel N, Naeyaert JM. Quality of life and stigmatization profile in a cohort of vitiligo patients and effect of the use of camouflage. Dermatology 2005;210:279-85.
42. Njoo MD, Vodegel RM, Westerhof W. Depigmentation therapy in vitiligo universalis with topical 4-methoxyphenol and the Q-switched ruby laser. J Am Acad Dermatol 2000;42:760-9.
43. Caron-Schreinemachers AL, Kingswijk MM, Bos JD, Westerhof W. UVB 311 nm tolerance of vitiligo skin increases with skin phototype. Acta Derm Venereol 2005;85:24-6.
44. Chiavérini C, Passeron T, Ortonne JP. Treatment of vitiligo by topical calcipotriol. J Eur Acad Dermatol Venereol 2002;16:137-8.
45. Seiter S, Ugurel S, Tilgen W, Reinhold U. Use of high-dose methylprednisolone pulse therapy in patients with progressive and stable vitiligo. Int J Dermatol 2000;39:624-7.
46. Radakovic-Fijan S, Fürnsinn-Friedl AM, Hönigsmann H, Tanew A. Oral dexamethasone pulse treatment for vitiligo. J Am Acad Dermatol 2001;44:814-7.
47. Gawkrodger DJ, Ormerod AD, Shaw L, et al. Guideline for the diagnosis and management of vitiligo. Br J Dermatol 2008;159:1051-76.
48. Parsad D, Gupta S. Standard guidelines of care for vitiligo surgery. Indian J Dermatol Venereol Leprol 2008;74:Suppl:S37-S45.